Drug
PF-06651600 clinical trials
Also written PF-06651600, Ritlecitinib and Litfulo.
Keep track of what changes. Save the PF-06651600 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Other names
Studies by the year they started
46 studies that test it; most in 2019 (10)
| Year | Studies |
|---|---|
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 5 |
| 2019 | 10 |
| 2020 | 6 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 6 |
| 2024 | 4 |
| 2025 | 4 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 40 · Other 6
Pfizer (40) · Icahn School of Medicine at Mount Sinai (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Massachusetts General Hospital (1) · Emma Guttman (1) · Ahuva D Cices (1)
Often tested with
Tested in the same studies.
PF-06700841 (4) · Zimlovisertib (2) · Abrocitinib (1) · Tolbutamide (1) · Tofacitinib (1) · Rifampin (1) · Sumatriptan (1) · Rosuvastatin (1)
Studies
Open first, then newest update. How each study uses PF-06651600 is read from its arms, and is right about nine times in ten.
Testing it · 46
- A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia AreataRecruitingPhase 3PfizerNCT06873945Written as Ritlecitinib 100 mg
- A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia AreataRecruitingPhase 3PfizerNCT07733765Written as Ritlecitinib 100 mg
- Ritlecitinib in Patients With Keloids or Those Undergoing KeloidectomyRecruitingPhase 2Icahn School of Medicine at Mount SinaiNCT06373458Written as Ritlecitinib
- A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.RecruitingPhase 2PfizerNCT07219615Written as Ritlecitinib 50 mg
- A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2Active, not recruitingPhase 3PfizerNCT06072183Written as Ritlecitinib
- A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.Active, not recruitingPhase 2PfizerNCT07228390Written as Ritlecitinib
- A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental VitiligoActive, not recruitingPhase 3PfizerNCT06163326Written as Ritlecitinib
- Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in RemissionCompletedPhase 2Massachusetts General HospitalNCT05636293Written as Ritlecitinib
- Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)Active, not recruitingPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT05743244Written as Ritlecitinib
- Ritlecitinib for Cicatricial AlopeciaCompletedPhase 2Emma GuttmanNCT05549934Written as PF-06651600
- Long-Term PF-06651600 for the Treatment of Alopecia AreataCompletedPhase 3PfizerNCT04006457Written as PF-06651600
- A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) TranquilloCompletedPhase 3PfizerNCT05583526Written as Ritlecitinib
- Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous UrticariaWithdrawnPhase 2Ahuva D CicesNCT06795373Written as Ritlecitinib
- Ritlecitinib in CTCLTerminatedPhase 2Icahn School of Medicine at Mount SinaiNCT05879458Written as Ritlecitinib
- PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATATerminatedPhase 2PfizerNCT04517864Written as PF-06651600
- A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy AdultsCompletedPhase 1PfizerNCT06172348Written as Ritlecitinib
- Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's DiseaseCompletedPhase 2PfizerNCT03395184Written as PF-06651600
- A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult ParticipantsCompletedPhase 1PfizerNCT05852340Written as Ritlecitinib
- A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of AgeCompletedPhase 1PfizerNCT05650333Written as Ritlecitinib 20 mg
- A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without FoodCompletedPhase 1PfizerNCT06369454Written as Ritlecitinib
See all 46 studies that test PF-06651600 →
As the comparator · 1 — what is tested is compared with PF-06651600
Codes
What other systems call PF-06651600 · ClinicalTrials.gg INT000617
- MeSH (NLM) C000614924PF-06651600One source NLM
- UNII (FDA) 2OYE00PC25RITLECITINIBConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000614924 | PF-06651600 | One source NLM |
| UNII (FDA) | 2OYE00PC25 | RITLECITINIB | Confirmed FDA, NLM |
Also registered as ritlecitinib tosylate (UNII EAG4T1459K).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.